Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage.

James E Cleaver, Angela M Brennan-Minnella, Raymond A Swanson, Ka-wing Fong, Junjie Chen, Kai-ming Chou, Yih-wen Chen, Ingrid Revet, Vladimir Bezrookove

Journal: Proceedings of the National Academy of Sciences of the United States of America 2015;111(37):13487-92

PMID: 25136123

Abstract

Cockayne syndrome (CS) is a human DNA repair-deficient disease that involves transcription coupled repair (TCR), in which three gene products, Cockayne syndrome A (CSA), Cockayne syndrome B (CSB), and ultraviolet stimulated scaffold protein A (UVSSA) cooperate in relieving RNA polymerase II arrest at damaged sites to permit repair of the template strand. Mutation of any of these three genes results in cells with increased sensitivity to UV light and defective TCR. Mutations in CSA or CSB are associated with severe neurological disease but mutations in UVSSA are for the most part only associated with increased photosensitivity. This difference raises questions about the relevance of TCR to neurological disease in CS. We find that CSB-mutated cells, but not UVSSA-deficient cells, have increased levels of intramitochondrial reactive oxygen species (ROS), especially when mitochondrial complex I is inhibited by rotenone. Increased ROS would result in oxidative damage to mitochondrial proteins, lipids, and DNA. CSB appears to behave as an electron scavenger in the mitochondria whose absence leads to increased oxidative stress. Mitochondrial ROS, however, did not cause detectable nuclear DNA damage even when base excision repair was blocked by an inhibitor of polyADP ribose polymerase. Neurodegeneration in Cockayne syndrome may therefore be associated with ROS-induced damage in the mitochondria, independent of nuclear TCR. An implication of our present results is that mitochondrial dysfunction involving ROS has a major impact on CS-B pathology, whereas nuclear TCR may have a minimal role.

Address: Department of Dermatology, University of California, San Francisco, CA 94143; [email protected].; Department of Neurology, University of California, San Francisco and Veterans Affairs Medical Center, San Francisco, CA 94121;; Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030;; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202;; Department of Dermatology, University of California, San Francisco, CA 94143; Department of Clinical Chemistry and Hematology, Sint Franciscus Gasthuis, 3045PM, Rotterdam, The Netherlands; and.; Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA 94107.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.